72
Views
15
CrossRef citations to date
0
Altmetric
Original Research

LncRNA NCK1-AS1 Promotes Cancer Cell Proliferation and Increase Cell Stemness in Urinary Bladder Cancer Patients by Downregulating miR-143

, , , , &
Pages 1661-1668 | Published online: 06 Mar 2020

References

  • Antoni S, Ferlay J, Soerjomataram I, et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur Urol. 2017;71(1):96–108. doi:10.1016/j.eururo.2016.06.01027370177
  • Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
  • Dobruch J, Daneshmand S, Fisch M, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol. 2016;69(2):300–310. doi:10.1016/j.eururo.2015.08.03726346676
  • Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234–241. doi:10.1016/j.eururo.2012.07.03322877502
  • Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol. 2001;19(3):666–675. doi:10.1200/JCO.2001.19.3.66611157016
  • Westhoff E, Witjes JA, Fleshner NE, et al. Body mass index, diet-related factors, and bladder cancer prognosis: a systematic review and meta-analysis. Bladder Cancer. 2018;4(1):91–112. doi:10.3233/BLC-17014729430510
  • Farid RM, Sammour SA-E, Shehab EZA, et al. Expression of CD133 and CD24 and their different phenotypes in urinary bladder carcinoma. Cancer Manag Res. 2019;11:4677–4690. doi:10.2147/CMAR.S19834831213893
  • Qin J, Wang Y, Bai Yet al,. Epigallocatechin-3-gallate inhibits bladder cancer cell invasion via suppression of nf-κb?mediated matrix metalloproteinase-9 expression. Mol Med Rep.2012;6:1040–1044.22941057
  • Anastasiadou E, L S J, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18(1):5–18. doi:10.1038/nrc.2017.9929170536
  • Esteller M. Non-coding RNAs in human disease. Nat Rev Cancer. 2011;12(12):861–874. doi:10.1038/nrg3074
  • Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing Mirna–Lncrna Interactions In Long Non-Coding RNAs. New York (NY): Humana Press; 2016:271–286.
  • Li H, Jia Y, Cheng J, et al. LncRNA NCK1-AS1 promotes proliferation and induces cell cycle progression by crosstalk NCK1-AS1/miR-6857/CDK1 pathway. Cell Death Dis. 2018;9(2):198. doi:10.1038/s41419-017-0249-329416014
  • Zhang WY, Liu YJ, He Y, et al. Suppression of long noncoding RNA NCK1-AS1 increases chemosensitivity to cisplatin in cervical cancer. J Cell Physiol. 2019;234(4):4302–4313. doi:10.1002/jcp.2719830221354
  • Zhihui. G, Yuwei. S, Jinguo. M, et al. Altered expression of lncRNA NCK1-AS1 distinguished patients with prostate cancer from those with benign prostatic hyperplasia. Oncol Lett. 2019;18(6):6379–6384. doi:10.3892/ol.2019.1103931807161
  • Chang Z-X, Tang N, Wang L, Zhang L-Q, Akinyemi IA, Wu Q-F. Identification and characterization of microRNAs in the white-backed planthopper, Sogatella furcifera. Insect Sci. 2016;23:452–468. doi:10.1111/ins.2016.23.issue-327060479
  • Simona. R, Scott. K, Ramana. D, Hamilton Stanley R, Calin George A. MicroRNAs, ultraconserved genes and colorectal cancers. Int J Biochem Cell Biol. 2010;42(8):1291–1297. doi:10.1016/j.biocel.2009.05.01819497386
  • Ohlsson Teague EMC, Print CG, Hull ML. The role of microRNAs in endometriosis and associated reproductive conditions. Hum Reprod Update. 2010;16:142–165. doi:10.1093/humupd/dmp03419773286
  • Noguchi S, Mori T, Hoshino Y, et al. MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells. Cancer Lett. 2011;307(2):211–220. doi:10.1016/j.canlet.2011.04.00521550168
  • Boubaker NS, Spagnuolo M, Trabelsi N, et al. miR-143 expression profiles in urinary bladder cancer: correlation with clinical and epidemiological parameters. Mol Biol Rep. 2020. doi:10.1007/s11033-019-05228-1
  • Zhang Q, Zhao W, Ye C. Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis. Oncotarget. 2015;6:37335–37348. doi:10.18632/oncotarget.613526484567
  • Pradella D, Naro C, Sette C, et al. EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression. Mol Cancer. 2017;16(1):8. doi:10.1186/s12943-016-0579-228137272
  • Zhang Y, Jin Z, Zhou H, et al. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin. Cancer Med. 2016;5(6):1251–1258. doi:10.1002/cam4.2016.5.issue-626899963
  • Gomes SE, Simões AES, Pereira DM, et al. miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells. Oncotarget. 2016;7(8):9368–9387. doi:10.18632/oncotarget.701026824186
  • Zhao S, Liu H, Liu Y, et al. miR-143 inhibits glycolysis and depletes stemness of glioblastoma stem-like cells. Cancer Lett. 2013;333(2):253–260. doi:10.1016/j.canlet.2013.01.03923376635